Source comparison
IGF-1 LR3 vs HGH: Protocol and Dosing Comparison
Research protocols using recombinant HGH typically employ doses ranging from 2–6 IU daily, split into two injections to maintain circulating levels throughout the 24-hour cycle. Peak serum GH occurs 3–4 hours post-injection, with IGF-1 levels rising 8–12 hours
This comparison does not assign a generated winner or score.
- Research protocols using recombinant HGH typically employ doses ranging from 2–6 IU daily, split into two injections to maintain circulating levels throughout the 24-hour cycle. Peak serum GH occurs 3–4 hours post-injection, with IGF-1 levels rising 8–12 hours later as hepatic synthesis ramps up. This delayed response means HGH's anabolic effects accumulate over days to weeks. Acute dosing doesn't produce immediate IGF-1 receptor activation.
- IGF-1 LR3 protocols use 20–80 mcg daily, administered once per day subcutaneously or intramuscularly. Receptor saturation occurs within 2–4 hours, and the 20–30 hour half-life ensures sustained signaling without requiring split dosing. The lower microgram dosing reflects potency differences. IGF-1 receptor binding affinity for LR3 is similar to native IGF-1, but the lack of IGFBP sequestration means effective tissue concentration remains higher for longer.
- Cycle length differs as well. HGH research cycles often run 3–6 months because the pituitary-hepatic axis takes weeks to reach steady-state IGF-1 elevation. IGF-1 LR3 cycles are typically shorter. 4–6 weeks. Because direct receptor activation produces measurable effects within days, and extended use may lead to receptor downregulation or hypoglycemic episodes if not carefully monitored. Our experience working with research teams shows that combining shorter LR3 cycles with structured washout periods often produces more consistent results than prolonged continuous administration.